Updated:
Huarun Zhengda Life Science Fund
Huarun Zhengda Life Science Fund is a life sciences investment vehicle linked to China's Huarun Group and Thailand's Zhengda Group, operating across Asia.
Huarun Zhengda Life Science Fund
Huarun Zhengda Life Science Fund was established as a joint investment platform between China Resources (Huarun) Group and Thailand's Charoen Pokphand Group (Zhengda). The fund focuses on life sciences, including pharmaceuticals, biotechnology, and healthcare services, across Asia. The fund deploys capital into direct investments and co-investments across the life sciences value chain — from early-stage biotech to established pharmaceutical firms. Geographic focus spans China and Southeast Asia, with offices in Shanghai, Shenzhen, Bangkok, and Hong Kong. Named portfolio companies or specific deal values have not been publicly disclosed. The fund's scale and team size remain undisclosed. Adjacent vehicles include the broader investment arms of Huarun Group and Charoen Pokphand Group, which operate across real estate, retail, finance, and other sectors. No recent operational events have been confirmed. A structural differentiator is the joint-venture model pairing a Chinese state-linked conglomerate with a Thai private business group, creating a rare cross-border life sciences investment platform. This architecture may provide portfolio companies with regulatory access and distribution channels across both markets.
General information
Firm type
Fund
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Additional offices
Shenzhen · Bangkok · Hong Kong
Sector focus
Frequently asked questions
What is the investment focus of Huarun Zhengda Life Science Fund?
The fund concentrates on life sciences, including pharmaceuticals, biotechnology, and healthcare services. It targets opportunities across the value chain from early-stage R&D to established manufacturing and distribution (public record).
Who are the parent entities behind Huarun Zhengda Life Science Fund?
The fund is a joint venture between China Resources (Huarun) Group, a Chinese state-owned conglomerate, and Charoen Pokphand Group (Zhengda), a Thai private business group. Both groups have extensive operations in their respective home markets (public record).
Where does Huarun Zhengda Life Science Fund operate geographically?
The fund has offices in Shanghai, Shenzhen, Bangkok, and Hong Kong, indicating a focus on Chinese and Southeast Asian markets (Altss estimate).
Does Huarun Zhengda Life Science Fund make direct investments or invest through funds?
The fund appears to make direct investments and co-investments in life sciences companies, leveraging the industry expertise and networks of its parent groups (Altss estimate).
Is information about the fund's size or portfolio holdings available?
No AUM, investment size, or specific portfolio company names have been publicly disclosed. The fund's scale and track record remain opaque (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: